These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28066420)

  • 1. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
    Derer A; Spiljar M; Bäumler M; Hecht M; Fietkau R; Frey B; Gaipl US
    Front Immunol; 2016; 7():610. PubMed ID: 28066420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.
    Kulzer L; Rubner Y; Deloch L; Allgäuer A; Frey B; Fietkau R; Dörrie J; Schaft N; Gaipl US
    J Immunotoxicol; 2014 Oct; 11(4):328-36. PubMed ID: 24512329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
    Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
    Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
    Kikuchi M; Clump DA; Srivastava RM; Sun L; Zeng D; Diaz-Perez JA; Anderson CJ; Edwards WB; Ferris RL
    Oncoimmunology; 2017; 6(7):e1329071. PubMed ID: 28811971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
    Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
    J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
    Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
    PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade.
    Dovedi SJ; Illidge TM
    Oncoimmunology; 2015 Jul; 4(7):e1016709. PubMed ID: 26140246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Molecular-level Changes of Programmed Cell Death Ligand-1 after Radiation Therapy in a BALB/c CT26 Colorectal Mouse Tumor Model.
    Khani Chamani F; Shabani M; Moradi A; Alinejad M; Jalali SA
    Iran J Allergy Asthma Immunol; 2023 Apr; 22(2):163-171. PubMed ID: 37496409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.
    Fujiwara M; Anstadt EJ; Clark RB
    Front Immunol; 2017; 8():42. PubMed ID: 28184224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.
    Iwasa M; Harada T; Oda A; Bat-Erdene A; Teramachi J; Tenshin H; Ashtar M; Oura M; Sogabe K; Udaka K; Fujii S; Nakamura S; Miki H; Kagawa K; Ozaki S; Abe M
    Oncotarget; 2019 Mar; 10(20):1903-1917. PubMed ID: 30956773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.
    Garbow JR; Johanns TM; Ge X; Engelbach JA; Yuan L; Dahiya S; Tsien CI; Gao F; Rich KM; Ackerman JJH
    Front Oncol; 2021; 11():693146. PubMed ID: 34249742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic alterations in PD-1/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model.
    Yoon YN; Choe MH; Kong M; Chung WK; Kim JS; Lim YJ
    Front Oncol; 2022; 12():989190. PubMed ID: 36479076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
    Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
    Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.